Αποτελέσματα αναζήτησης - "клинико-экономическая оценка"

1

Academic Journal

Pharmacoeconomic aspects of the targeted drugs use in psoriatic arthritis in context of the Russian healthcare system ; Фармакоэкономические аспекты применения таргетных препаратов при псориатическом артрите в условиях системы здравоохранения Российской Федерации

Συγγραφείς: O. I. Ivakhnenko, T. V. Korotaeva, T. V. Dubinina, A. M. Lila, О. И. Ивахненко, Т. В. Коротаева, Т. В. Дубинина, А. М. Лила

Πηγή: Modern Rheumatology Journal; Том 16, № 5 (2022); 28-37 ; Современная ревматология; Том 16, № 5 (2022); 28-37 ; 2310-158X ; 1996-7012

Θεματικοί όροι: затраты на одного ответившего на лечение пациента, drugs, clinical and economic assessment, costs per responding patient, лекарственные препараты, клинико-экономическая оценка

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1342/1283; Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018; 46(1):32-9.; Лила АМ, Древаль РО, Шипицын ВВ. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социально-экономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3):112-9. doi:10.14412/1996-7012-2018-3-112-119; Круглова ЛС, Хотко АА. Ресурсопотребление и трудоспособность пациентов на фоне применения системной терапии и генно-инженерной биологической терапии. Качественная клиническая практика. 2021;(1):46-55.; Degli Esposti L, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018 Nov 12;12: 151-8. doi:10.2147/BTT.S168691. eCollection 2018.; Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi:10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.; Коротаева ТВ, Корсакова ЮЛ, Логинова ЕЮ и др. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018; 12(2):22-35. [Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(2): 22-35. (In Russ.). doi:10.14412/1996-7012-2018-2-22-35; http://www.prisma-statement.org/PRISMAStatement/FlowDiagram; Cochrane Handbook for Systematic Reviews of Interventions. Chapter 10: Analysing data and undertaking meta-analyses. https://training.cochrane.org/handbook/current/chapter-10; PRISMA Flow Diagram URL: http://www.prisma-statement.org/PRISMAStatement/FlowDiagram; Mease PJ, Gladman DD, Ritchlin CT, et al; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi:10.1002/art.21306.; Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-25. doi:10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13.; Mease PJ, Rahman P, Gottlieb AB, et al; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126-36. doi:10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.; McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137-46. doi:10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.; Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018 Mar 15;20(1):47. doi:10.1186/s13075-018-1551-x.; Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, doubleblind, phase III FUTURE 5 study. Ann Rheum Dis. 2018 Jun;77(6):890-7. doi:10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.; Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16): 1537-50. doi:10.1056/NEJMoa1615975.; Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-36. doi:10.1056/NEJMoa1615977.; McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780-9. doi:10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.; Ritchlin C, Rahman P, Kavanaugh A, et al; PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun;73(6):990-9. doi:10.1136/annrheumdis2013-204655. Epub 2014 Jan 30.; Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III doubleblind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014 Jan; 73(1):233-7. doi:10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13.; McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13): 1227-39. doi:10.1056/NEJMoa2022516.; Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020 Dec 3;80(3):312–20. doi:10.1136/annrheumdis-2020-218870. Epub ahead of print.; Mease PJ, van der Heijde D, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi:10.1136/annrheumdis2016-209709. Epub 2016 Aug 23.; Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebocontrolled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 Jun 10;389(10086):2317-27. doi:10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.; https://handbook-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm; Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017 Dec; 20(12):1224-30. doi:10.1080/13696998.2017.1362413. Epub 2017 Aug 22.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1342
https://doi.org/10.14412/1996-7012-2022-5-28-37

View record from BASE

2

Academic Journal

Clinical and economic evaluation of the use of biologic disease-modifying antirheumatic drugs and targeted synthetic antirheumatic drugs for ankylosing spondylitis in context of the Russian healthcare system ; Клинико-экономическая оценка применения генно-инженерных биологических препаратов и таргетных синтетических препаратов при анкилозирующем спондилите в условиях системы здравоохранения Российской Федерации

Συγγραφείς: O. I. Ivakhnenko, T. V. Dubinina, T. V. Korotaeva, A. M. Lila, О. И. Ивахненко, Т. В. Дубинина, Т. В. Коротаева, А. М. Лила

Πηγή: Modern Rheumatology Journal; Том 16, № 4 (2022); 46-56 ; Современная ревматология; Том 16, № 4 (2022); 46-56 ; 2310-158X ; 1996-7012

Θεματικοί όροι: затраты на одного ответившего на лечение пациента, clinical and economic assessment, costs per responding patient, клинико-экономическая оценка

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1322/1268; Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021 Dec 19;396(10267):2006-17. doi:10.1016/S0140-6736(20)32340-0. Epub 2020 Dec 1.; Shah K, Paris M, Mellars L, et al. Realworld burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017 Dec 28;3(2):e000588. doi:10.1136/rmdopen-2017-000588.; Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;46(1):32-9.; Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015 Apr 8; 10(4):e0123582. doi:10.1371/journal.pone.0123582.; Mease PJ, Liu M, Rebello S, et al. Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries. Rheumatol Ther. 2019 Dec;6(4): 529-42. doi:10.1007/s40744-019-00172-9. Epub 2019 Sep 16.; Лила АМ, Дубинина ТВ, Древаль РО и др. Медико-социальная значимость и расчет экономического бремени аксиального спондилоартрита в Российской Федерации. Современная ревматология. 2022;16(1):20-5. doi:10.14412/1996-7012-2022-1-20-25; Круглова ЛС, Хотко АА. Ресурсопотребление и трудоспособность пациентов на фоне применения системной терапии и генно-инженерной биологической терапии. Качественная клиническая практика. 2021;(1):46-55.; Degli Esposti L, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018 Nov 12;12:151-8. doi:10.2147/BTT.S168691. eCollection 2018.; Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi:10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.; Лила АМ, Древаль РО, Шипицын ВВ. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социальноэкономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3):112-9. doi:10.14412/1996-7012-2018-3-112-119; Жильцов ИВ, Кундер ЕВ. Персонализированное лечение анкилозирующего спондилита. https://cyberleninka.ru/article/n/personalizirovannoelechenie-ankiloziruyuschego-spondilita; Cochrane Handbook for Systematic Reviews of Interventions. Chapter 10: Analysing data and undertaking meta-analyses. URL: https://training.cochrane.org/handbook/current/chapter-10; Van der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul;54(7):2136-46. doi:10.1002/art.21913.; Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12. doi:10.1002/art.23969.; Van der Heijde D, Cheng-Chung WJ, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, activecontrolled and placebo-controlled trial. Lancet. 2018 Dec 8;392(10163):2441-51. doi:10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.; Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22; 19(1):285. doi:10.1186/s13075-017-1490-y.; Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr 27;80(8):1004–13. doi:10.1136/annrheumdis-2020-219601. Epub ahead of print.; Deodhar A, van der Heijde D, Sieper J, et al. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. 2022 Jan;74(1):70-80. doi:10.1002/art.41911. Epub 2021 Nov 12.; Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014 Jan; 73(1):39-47. doi:10.1136/annrheumdis-2013-204231. Epub 2013 Sep 6.; Dougados M, Braun J, Szanto S, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford). 2012 Sep; 51(9):1687-96. doi:10.1093/rheumatology/kes125.; https://handbook-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm; Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017 Dec;20(12):1224-30. doi:10.1080/13696998.2017.1362413. Epub 2017 Aug 22.; Laupacis A, Sackett DL, Roberts RS. An Assessment of Clinically Useful Measures of the Consequences of Treatment. N Engl J Med. 1988 Jun 30;318(26):1728-33. doi:10.1056/NEJM198806303182605.; Garg V, Shen X, Cheng Y, et al. Use of number needed to treat in cost-effectiveness analyses. Ann Pharmacother. 2013 Mar;47(3): 380-7. doi:10.1345/aph.1R417. Epub 2013 Mar 5.; Филиппова АВ, Колбин АС. Соответствие результатов клинических исследований и реальной медицинской практики. Ученые записки СПбГМУ им. акад. И.П. Павлова. 2018;25(1):7-14.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1322
https://doi.org/10.14412/1996-7012-2022-4-46-56

View record from BASE

3

Academic Journal